$4.56
-0.26 (-5.39%)
Open$4.79
Previous Close$4.82
Day High$4.93
Day Low$4.40
52W High$16.34
52W Low$2.39
Volume—
Avg Volume122.1K
Market Cap176.21M
P/E Ratio—
EPS$-7.76
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+282.7% upside
Current
$4.56
$4.56
Target
$17.45
$17.45
$10.78
$17.45 avg
$19.60
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.53M | 5.75M | 51.72M |
| Net Income | -196,077,611 | -183,459,663 | -16,237,176 |
| Profit Margin | -3,544.0% | -3,366.8% | -31.4% |
| EBITDA | -39,600,653 | -39,110,739 | -19,844,642 |
| Free Cash Flow | — | — | -12,228,215 |
| Rev Growth | -3.8% | -3.8% | -2.8% |
| Debt/Equity | — | — | 1.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $258.92 | +3.43% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $425.28 | +1.41% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $143.44 | +3.25% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $528.19 | +2.45% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $810.24 | +0.53% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.61 | +1.79% | 37.6 | 30.39B |